US Patent:
20050058651, Mar 17, 2005
Inventors:
Peter Thomas - Pembroke, MA, US
Olga Bajenova - Somerville MA, US
International Classification:
C12Q001/68
G01N033/574
C07H021/04
A61K039/395
C12N009/64
US Classification:
424155100, 514044000, 435006000, 435007230, 435069100, 435226000, 435320100, 435325000, 530388260, 536023200
Abstract:
We have now discovered a new method for treating carcinoembriyonic antigen (CEA) associated cancers. This involves blocking a protein expressed by the hnRNP M4 gene (preferably the human hnRNP M4 gene). We identified and isolated a liver-derived recombinant cDNA clone, termed heterogeneous nuclear RNA binding protein M4 (hnRNP M4) SEQ ID NO: 1, from rat macrophages Kupffer cells (KC) that encodes a novel protein interacting with CEA molecules and is 91% homologous with the deletion mutant of the human hnRNP M4 gene (# U32577). The novel protein is, hereinafter, considered as one protein population with the human homologue and referred to herein as hnRNP M4 CEA receptor, or hnRNP M4.
